May ischemia modified albumin be a predictor in diagnosis of contrast induced nephropathy?
Omercan Topaloglu1, Bilgin Demir2, Ferhat Ekinci2, Mehmet Uzun2, Yusuf Kurtulmus3, Hakan Turkon4, Can Duman4, Harun Akar5 ,Mehmet Tanrisev5
1Inonu University Faculty of Medicine, Department of Endocrinology, Malatya, Turkey
2Izmir Tepecik Training and Research Hospital, Department of Internal Medicine, Izmir, Turkey
3Adnan Menderes University Medical Faculty, Department of Medical Biochemistry, Aydin, Turkey
4Canakkale Onsekiz Mart University Faculty of Medicine, Department of Biochemistry, Canakkale, Turkey
5Izmir Tepecik Training and Research Hospital, Department of Nephrology, Izmir, Turkey
Aim: “Ischemia modified albumin” (IMA) was investigated as a possible biomarker in several diseases such as vascular disorders. We aimed to reveal the possible value of IMA in predicting the development of contrast induced nephropathy (CIN) after coronary angiography in patients with stable angina pectoris.
Material and Methods: 106 patients underwent coronary angiography with a diagnosis of stable angina pectoris were included in our study. Basic demographic and clinical findings and laboratory values were recorded and analyzed. Serum creatinine (SCre) levels were also measured 48 hours after coronary angiography and recorded. Amount of contrast agent (CA) given during coronary angiography was recorded. The patients were divided into 2 groups: CIN positive and CIN negative groups.
Results: CIN was developed in 14 patients (13%); and IMA levels were similar in CIN positive and negative groups (p>0.05). SCre (both measurements before and after CA administration) was not correlated with IMA levels. There was no association between drug usage and development of CIN (p>0.05). Comorbidities were not associated with the development of CIN (p>0.05) with the exception of hypertension (HT). Presence of hypertension (p=0.0393) and female gender (p=0.0199) was associated with development of CIN. Mean age was 61.3 and 52.3 in CIN positive and negative groups, respectively (p>0.05).
Conclusion: Any specific biomarker indicating CIN is not available yet. Most frequently used marker is the measurement of SCre 24-48 hours after administration of CA. We found IMA levels not to be a predictor for the development of CIN. Further investigations will clearly determine the importance of IMA as a biomarker in renal failure developed after CA administration.